| Name | Title | Contact Details |
|---|
Rooted in Relationships, Backed by Results. Our Mission is to revolutionize the perception and impact of employee well-being by creating and proving the correlation of employee well-being with bottom line revenue. To help medium and large-sized organizations by deploying and managing tailored programs that are customized for every client and personalized for each participant. To deliver total Return on Well-being for every client, including individual health improvement, heightened employee engagement, increased productivity, cultural improvement, lower healthcare costs, and higher profitability. Our Vision is to revolutionize the way corporate America values employee well-being by correlating improved employee health and employee engagement with decreased human resources costs and improved financial performance. Our Purpose is to impact our clients’ success and the quality of life of each individual we touch. Through Guaranteed Support; Guaranteed Enjoyment; Guaranteed Improvement you’ll see how we can impact your Return on Well-being (ROW) and improve the health and well-being of your workforce. Connect with us to start the change!
cambridge healthcare is a Chantilly, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Albion Laboratories is a Clearfield, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Capital Health Plan is a Tallahassee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.